WOCKPHARMA - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.2
| Stock Code | WOCKPHARMA | Market Cap | 22,931 Cr. | Current Price | 1,413 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 163 | Book Value | 178 ₹ | Dividend Yield | 0.00 % | ROCE | 4.40 % |
| ROE | -0.53 % | Face Value | 5.00 ₹ | DMA 50 | 1,385 ₹ | DMA 200 | 1,395 ₹ |
| Chg in FII Hold | -0.10 % | Chg in DII Hold | -0.45 % | PAT Qtr | 54.0 Cr. | PAT Prev Qtr | 69.0 Cr. |
| RSI | 54.1 | MACD | -10.0 | Volume | 8,54,933 | Avg Vol 1Wk | 5,18,440 |
| Low price | 1,110 ₹ | High price | 1,870 ₹ | PEG Ratio | 6.73 | Debt to equity | 0.76 |
| 52w Index | 39.9 % | Qtr Profit Var | 250 % | EPS | 8.68 ₹ | Industry PE | 29.1 |
📊 Analysis: WOCKPHARMA is trading at ₹1,413, slightly above both 50 DMA (₹1,385) and 200 DMA (₹1,395), showing short-term support. RSI (54.1) is neutral, while MACD (-10.0) signals bearish divergence, indicating caution. Intraday volume (8.5 lakh) is higher than the 1-week average (5.1 lakh), suggesting active trader participation. Fundamentals remain weak with high P/E (163), low ROCE (4.40%), and negative ROE (-0.53%). The stock may offer speculative intraday opportunities but carries elevated risk.
💡 Optimal Buy Price: ₹1,405–₹1,415 if price consolidates near support.
🎯 Profit-Taking Exit Levels: ₹1,435–₹1,455 (short-term resistance zone).
🛡️ Stop-Loss Protection: ₹1,390 (below recent support).
⏱️ If Already Holding: Consider exiting intraday if price fails to sustain above ₹1,430 or if RSI dips below 52 with weakening volume. Quick profit booking is advisable given mixed momentum signals.
✅ Positive
- Stock trading above both 50 DMA and 200 DMA, showing short-term strength.
- Quarterly profit variation (+250%) indicates sharp improvement.
- EPS of ₹8.68 provides earnings visibility.
- Strong intraday volume compared to average, showing trader interest.
⚠️ Limitation
- Extremely high P/E (163) compared to industry average (29.1).
- ROCE (4.40%) and ROE (-0.53%) remain weak.
- Debt-to-equity ratio at 0.76, indicating high leverage.
- MACD remains negative, signaling short-term weakness.
📉 Company Negative News
- FII holdings reduced (-0.10%).
- DII holdings reduced (-0.45%).
- Quarterly PAT declined sequentially (₹54 Cr vs ₹69 Cr).
📈 Company Positive News
- Quarterly profit variation (+250%) shows strong YoY recovery.
- Stock trading above DMA levels, reflecting short-term support.
🏭 Industry
- Industry PE is 29.1, much lower than WOCKPHARMA’s valuation, suggesting premium pricing.
- Pharmaceutical sector remains resilient but faces regulatory and margin pressures.
🔎 Conclusion
WOCKPHARMA shows moderate potential for intraday trading today with strong volume and support above DMA levels. However, weak fundamentals, high leverage, and negative MACD suggest caution. Best suited for speculative short-duration trades with tight stop-losses rather than aggressive intraday positions.